Background
Materials and methods
Participants
Clinical and laboratory findings
Renal histopathology
Treatment
Statistical analyses
Results
No differences in baseline clinical test characteristics, with the exception of platelet counts, were observed among patients who acquired complete renal recovery, partial renal recovery, or who remained dialysis dependent
Feature | Patients with complete renal recovery (n = 13) | Patients with partial renal recovery (n = 12) | Patients remaining on dialysis (n = 15) | P value |
---|---|---|---|---|
Male/female | 9/4 | 6/6 | 6/9 | 0.297 |
Age (years) | 63.1 ± 9.5 | 57.7 ± 7.3 | 55.9 ± 15.1 | 0.252 |
Time from first symptom (days) | 70.7 ± 75.9 | 110.0 ± 112.4 | 92.1 ± 46.1 | 0.674 |
BVAS | 23.3 ± 6.3 | 19.9 ± 5.0 | 22.0 ± 6.3 | 0.368 |
Fever (Y/N) | 8/5 | 8/4 | 8/7 | 0.774 |
Weight loss (Y/N) | 5/6 | 4/8 | 5/10 | 0.781 |
Muscle/joint (Y/N) | 3/10 | 3/9 | 3/12 | 0.952 |
Skin (Y/N) | 1/12 | 0/12 | 3/12 | 0.215 |
Eyes/mucous membranes (Y/N) | 3/10 | 2/10 | 3/12 | 0.923 |
Ear/nose/throat (Y/N) | 6/7 | 5/7 | 4/11 | 0.534 |
Lung (Y/N) | 8/5 | 4/8 | 7/8 | 0.368 |
Cardiovascular (Y/N) | 1/12 | 0/12 | 0/15 | 0.345 |
Digestive tract (Y/N) | 2/11 | 4/8 | 2/13 | 0.382 |
Nervous system (Y/N) | 3/10 | 2/10 | 2/13 | 0.792 |
Gross hematuria (Y/N) | 0/13 | 2/10 | 1/14 | 0.283 |
ANCA level (IU/mL) | 89.3 ± 21.7 | 101.7 ± 36.0 | 94.9 ± 34.0 | 0.847 |
eGFR (mL/min/1.73m2) | 7.0 ± 2.3 | 6. 6 ± 2.1 | 5.7 ± 1.8 | 0.231 |
Proteinuria (g/24 h) | 2.8 ± 2.3 | 2.5 ± 3.0 | 3.5 ± 1.7 | 0.641 |
Hemoglobumin (g/L) | 8.5 ± 1.7 | 7.9 ± 1.0 | 7.3 ± 1.5 | 0.095 |
White blood cell (109/L) | 9.3 ± 2.7 | 8.0 ± 3.1 | 10.2 ± 6.8 | 0.507 |
Platelet (109/L) | 326.3 ± 160.4 | 269.3 ± 137.1 | 201.2 ± 66.4 | 0.040 |
ESR (mm/h) | 83.2 ± 41.0 | 71.9 ± 39.4 | 82.5 ± 45.2 | 0.756 |
Serum albumin (g/L) | 28.4 ± 5.5 | 27.3 ± 7.3 | 28.1 ± 6.9 | 0.275 |
Serum calcium (mmol/L) | 2.0 ± 0.4 | 1.9 ± 0.4 | 1.8 ± 0.4 | 0.374 |
Serum phosphate (mmol/L) | 1.7 ± 0.4 | 1.7 ± 0.4 | 1.7 ± 0.3 | 0.215 |
Serum PTH (pg/mL) | 128.4 ± 95.3 | 131.4 ± 86.3 | 137.0 ± 93.4 | 0.114 |
Increased RF (Y/N) | 7/6 | 3/9 | 3/12 | 0.130 |
C-reactive protein (mg/dL) | 4.6 (0.9, 15.6) | 1.8 (0.2, 8.7) | 1.9 (0.3, 16.3) | 0.105 |
Complement 3 (mg/dL) | 88.7 ± 33.3 | 82.7 ± 23.9 | 89.0 ± 23.6 | 0.896 |
Complement 4 (mg/dL) | 19.0 ± 8.3 | 23.8 ± 3.2 | 30.7 ± 8.0 | 0.113 |
Renal histopathological characteristics were strongly associated with the kidney prognosis
Feature | Patients with complete renal recovery (n = 13) | Patients with partial renal recovery (n = 12) | Patients remaining on dialysis (n = 15) | P value |
---|---|---|---|---|
Normal glomeruli (%) | 24.2 (0.0, 57.2) | 11.3 (0.0, 40.0) | 0.0 (0.0, 15.2) | 0.007 |
Fibrinoid necrosis (%) | 3.8 (0.0, 16.7) | 0.0 (0.0, 10.0) | 0.0 (0.0, 3.1) | 0.065 |
Cellular crescent (%) | 58.1 (19.0, 100.0) | 50.8 (20.0, 80.0) | 31.7 (3.9, 65.6) | 0.015 |
Fibrous crescent (%) | 6.3 (0.0, 40.7) | 18.8 (9.7, 31.4) | 40.3 (0.0, 82.9) | < 0.001 |
Global glomerulosclerosis (%) | 0.0 (0.0, 33.3) | 2.5 (0.0, 14.8) | 20.0 (0.0, 40.0) | < 0.001 |
Interstitial infiltrates (−/+/++/+++) | 1/2/6/4 | 1/0/5/6 | 0/2/8/5 | 0.694 |
Interstitial fibrosis (−/+/++) | 5/7/1 | 2/5/5 | 1/8/6 | 0.133 |
Tubular atrophy (−/+/++) | 1/7/5 | 0/3/9 | 0/4/11 | 0.213 |
Arterial wall thickening (−/+) | 5/8 | 0/12 | 0/15 | 0.003 |
Mixed class of pathological classification is associated with poor kidney outcome
Feature | Patients who entered ESRD (n = 3) | Patients who did not enter ESRD (n = 9) | P value |
---|---|---|---|
Normal glomeruli (%) | 0.0 (0.0, 4.0) | 14.3 (5.0, 36.7) | 0.405 |
Fibrinoid necrosis (%) | 0.0 (0.0, 0.0) | 0.0 (0.0, 10.0) | 0.275 |
Cellular crescent (%) | 48.6 (20.0, 80.0) | 51.5 (33.3, 74.2) | 0.782 |
Fibrous crescent (%) | 30.0 (13.3, 31.4) | 18.2 (9.7, 30.0) | 0.195 |
Global glomerulosclerosis (%) | 0.0 (0.0, 14.8) | 10.0 (6.7, 14.3) | 0.038 |
Pathological classification (F/C/M/S) | 0/0/3/0 | 0/6/3/0 | 0.046 |
Percentage of fibrous crescent+global glomerulosclerosis was a marker to predict the kidney outcome
PE treatment accelerated the renal recovery
MP vs. PE | Pulse CTX vs. Oral CTX | |||||
---|---|---|---|---|---|---|
MP (n = 26) | PE (n = 14) | P value | Pulse CTX (n = 10) | Oral CTX (n = 30) | P value | |
MP/PE | – | – | – | 7/3 | 19/11 | 0.702 |
Pulse CTX/Oral CTX | 7/19 | 3/11 | 0.702 | – | – | – |
BVAS | 22.9 ± 6.2 | 19.9 ± 5.1 | 0.132 | 23.4 ± 4.9 | 21.3 ± 6.2 | 0.333 |
eGFR (mL/min/1.73 m2) | 6.4 ± 2.0 | 6.2 ± 2.3 | 0.774 | 6.6 ± 2.1 | 6.3 ± 2.1 | 0.646 |
Proteinuria (g/24 h) | 2.7 ± 1.7 | 3.3 ± 3.2 | 0.384 | 2.8 ± 2.1 | 3.0 ± 2.5 | 0.848 |
Gross hematuria (Y/N) | 3/23 | 0/14 | 0.186 | 1/9 | 2/28 | 0.729 |
Renal recovery (CR/PR/N) | 7/7/12 | 6/5/3 | 0.297 | 3/4/3 | 10/8/12 | 0.715 |
Time for getting dialysis independence (days) | 41.4 ± 11.7 | 29.4 ± 15.6 | 0.039 | 34.8 ± 11.1 | 36.3 ± 15.9 | 0.894 |